Cover Image
Market Research Report

Omeros Corporation - Product Pipeline Review - 2016

Published by Global Markets Direct Product code 203730
Published Content info 115 Pages
Delivery time: 1-2 business days
Price
Back to Top
Omeros Corporation - Product Pipeline Review - 2016
Published: August 10, 2016 Content info: 115 Pages
Description

Summary:

Global Markets Direct's, 'Omeros Corporation - Product Pipeline Review - 2016', provides an overview of the Omeros Corporation's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Omeros Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Omeros Corporation
  • The report provides overview of Omeros Corporation including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Omeros Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Omeros Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Omeros Corporation's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Omeros Corporation
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Omeros Corporation's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Product Code: GMDHC08113CDB

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Omeros Corporation Snapshot
    • Omeros Corporation Overview
    • Key Information
    • Key Facts
  • Omeros Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Omeros Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Omeros Corporation - Pipeline Products Glance
  • Omeros Corporation - Late Stage Pipeline Products
  • Omeros Corporation - Clinical Stage Pipeline Products
  • Omeros Corporation - Early Stage Pipeline Products
  • Omeros Corporation - Drug Profiles
    • OMS-721
    • OMS-405
    • OMS-824
    • Monoclonal Antibodies for Oncology, Metabolic, Cardiovascular and Musculoskeletal Disorders
    • Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications
    • OMS-527
    • OMS-616
    • OMS-906
    • Small Molecule to Agonize GPR52 for Schizophrenia
    • Small Molecule to Agonize PTH-1R for Osteoporosis
    • Small Molecule to Antagonize GPR101 for Appetite Disorders
    • Small Molecule to Antagonize GPR12 for Obesity, Cognitive Impairments and Motor Disorders
    • Small Molecule to Antagonize GPR139 for Motor Disorders
    • Small Molecule to Antagonize GPR15 for Rheumatoid Arthritis and HIV-Mediated Enteropathy
    • Small Molecule to Antagonize GPR161 for Oncology, Ophthalmology and Central Nervous System Disorders
    • Small Molecule to Antagonize GPR17 for Central Nervous System Disorders
    • Small Molecule to Antagonize GPR173 for Obesity and Schizophrenia
    • Small Molecule to Antagonize GPR182 for Pancreatic Cancer
    • Small Molecule to Antagonize GPR19 for Metastatic Melanoma and Lung Cancer
    • Small Molecule to Antagonize GPR20 for Gastro-Intestinal Stromal Tumors and Acute Myeloid Leukemia
    • Small Molecule to Antagonize GPR27 for Obesity, Diabetes and Schizophrenia
    • Small Molecule to Antagonize GPR31 for Anxiety Disorders
    • Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes
    • Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia
    • Small Molecule to Antagonize GPR85 for Obesity and Schizophrenia
    • Small Molecule to Antagonize GPR87 for Oncology
    • Small Molecule to Antagonize NMUR2 for Pain
    • Small Molecule to Antagonize OPN4 for Circadian Rhythm Irregularities and Sleep Disorders
    • Small Molecule to Antagonize P2Y8 for Acute Lymphoblastic Leukemia and Lymphoma
    • Small Molecule to Inhibit CCRL2 for Rheumatoid Arthritis and Immune Disorders
    • Small Molecule to Target GPR132 for Cardiovascular Diseases
    • Small Molecule to Target GPR135
    • Small Molecule to Target GPR141 for Respiratory and Immune Disorders
    • Small Molecule to Target GPR150 for Ovarian Cancer
    • Small Molecule to Target GPR151 for CNS Diseases
    • Small Molecule to Target GPR153 for Schizophrenia
    • Small Molecule to Target GPR162 for Neuropsychiatric Disorders
    • Small Molecule to Target GPR171 for Eating and Hematological Disorders
    • Small Molecule to Target GPR174 for Immunology, Neurology and Oncology
    • Small Molecule to Target GPR183 for Osteoporosis and Epstein-Barr Viral Infections
    • Small Molecule to Target GPR21 for Obesity and Diabetes
    • Small Molecule to Target GPR22 for Anxiety, Cardiovascular Diseases and Osteoarthritis
    • Small Molecule to Target GPR25 for Arterial Stiffness
    • Small Molecule to Target GPR32 for Acute Inflammation
    • Small Molecule to Target GPR37 for Parkinson's Disease
    • Small Molecule to Target GPR37L1 for Hypertension and Cardiac Hypertrophy
    • Small Molecule to Target GPR45
    • Small Molecule to Target GPR50 for CNS and Metabolic Disorders
    • Small Molecule to Target GPR63 for Autism
    • Small Molecule to Target GPR65 for Oncology and Inflammatory Disorders
    • Small Molecule to Target GPR80 for Hepatocellular Carcinoma
    • Small Molecule to Target GPR82 for Appetite Disorders and Body Weight
    • Small Molecule to Target GPR83 for CNS and Immunological Disorders
    • Small Molecule to Target LGR4 for Oncology and Osteoporosis
    • Small Molecule to Target LGR5 for Esophageal Adenocarcinoma
    • Small Molecule to Target LGR6 for Dermatology
    • Small Molecule to Target MAS1 for Cognitive Impairments, Blood Pressure Abnormalities and Colon Cancer
    • Small Molecule to Target MRGE for Pain
    • Small Molecule to Target MRGF
    • Small Molecule to Target OGR1 for Oncology, Bone Diseases, Asthma and Osteoporosis
    • Small Molecule to Target OPN5
    • Small Molecules to Agonize GPR61 for Eating Disorder
    • Small Molecules to Target GPR146 for Metabolic Disorders
    • Omeros Corporation - Pipeline Analysis
    • Omeros Corporation - Pipeline Products by Target
    • Omeros Corporation - Pipeline Products by Route of Administration
    • Omeros Corporation - Pipeline Products by Molecule Type
    • Omeros Corporation - Pipeline Products by Mechanism of Action
    • Omeros Corporation - Recent Pipeline Updates
    • Omeros Corporation - Dormant Projects
    • Omeros Corporation - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Omeros Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Omeros Corporation, Key Information
  • Omeros Corporation, Key Facts
  • Omeros Corporation - Pipeline by Indication, 2016
  • Omeros Corporation - Pipeline by Stage of Development, 2016
  • Omeros Corporation - Monotherapy Products in Pipeline, 2016
  • Omeros Corporation - Phase III, 2016
  • Omeros Corporation - Phase II, 2016
  • Omeros Corporation - Preclinical, 2016
  • Omeros Corporation - Discovery, 2016
  • Omeros Corporation - Pipeline by Target, 2016
  • Omeros Corporation - Pipeline by Route of Administration, 2016
  • Omeros Corporation - Pipeline by Molecule Type, 2016
  • Omeros Corporation - Pipeline Products by Mechanism of Action, 2016
  • Omeros Corporation - Recent Pipeline Updates, 2016
  • Omeros Corporation - Dormant Developmental Projects,2016
  • Omeros Corporation - Discontinued Pipeline Products, 2016
  • Omeros Corporation, Subsidiaries

List of Figures

  • Omeros Corporation - Pipeline by Top 10 Indication, 2016
  • Omeros Corporation - Pipeline by Stage of Development, 2016
  • Omeros Corporation - Monotherapy Products in Pipeline, 2016
  • Omeros Corporation - Pipeline by Top 10 Target, 2016
  • Omeros Corporation - Pipeline by Route of Administration, 2016
  • Omeros Corporation - Pipeline by Molecule Type, 2016
  • Omeros Corporation - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top